Overview
- Senhwa Biosciences signed a Memorandum of Understanding with GEM Yield Bahamas Limited for up to NT$500 million, or about US$16 million.
- The company says the potential funding would advance its clinical programs, scale its AI discovery work, and support international growth.
- Senhwa is working with CellType to apply cell-to-sentence technology that turns complex cell data into machine-readable summaries to spot combination therapies.
- Company-run AI checks suggest its lead drug candidates can help turn some tumors from “cold” to “hot,” which may improve responses to immunotherapy.
- The MOU sets out intent rather than a completed deal, and the parties still need to finalize binding terms before any investment occurs.